![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205104
https://www.fiercepharma.com/pharma/uzedy-partners-teva-and-medincells-latest-long-acting-schizophrenia-candidate-notches-phase
https://www.fiercepharma.com/pharma/teva-medincell-win-fda-approval-slow-release-schizophrenia-drug-uzedy
https://www.pharmaceutical-technology.com/news/fda-schizophrenia-treatment-rykindo/
https://www.usnews.com/news/top-news/articles/2021-10-30/j-j-settles-most-risperdal-lawsuits-with-800-million-in-expenses
https://www.businesswire.com/news/home/20211021005210/en/Teva-to-Present-New-Data-from-Growing-Mental-Health-Portfolio-at-Psych-Congress-2021
https://www.biospace.com/article/releases/indivior-takes-strategic-alignment-actions/
https://www.biospectrumasia.com/news/34/15177/china-grants-priority-review-to-luye-pharmas-schizophrenia-drug.html
https://www.fiercepharma.com/pharma/j-j-recalls-one-lot-talc-and-investors-wipe-away-billions
https://www.fiercepharma.com/marketing/j-j-litigation-hot-seat-can-it-hold-off-long-term-brand-and-reputation-damage
https://www.fiercepharma.com/pharma/johnson-johnson-s-shares-historically-cheap-possible-talc-opioid-deals-give-analysts-hopes
https://www.fiercepharma.com/pharma/jury-hits-j-j-8b-risperdal-verdict-but-will-it-stand-up-appeals
https://www.forbes.com/sites/rachelsandler/2019/10/08/johnson--johnson-ordered-to-pay-8-million-in-male-breast-growth-case/#4cf817801f8b
https://www.reuters.com/article/us-indivior-perseris-canada/indivior-signs-deal-to-sell-schizophrenia-drug-in-canada-idUSKCN1SF185
https://www.biospace.com/article/releases/luye-pharma-announces-innovative-drug-risperidone-extended-release-microspheres-for-injection-has-reached-final-stage-of-nda-process/
https://pharmaphorum.com/news/indivior-hit-hard-as-generic-suboxone-defence-crumbles/
https://www.prnewswire.com/news-releases/durect-announces-fda-approval-of-indiviors-perseris-risperidone-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia-in-adults-300688221.html
https://www.prnewswire.com/news-releases/fda-approves-perseris-risperidone-for-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia-in-adults-300688082.html
https://pharmaphorum.com/news/indivior-schizophrenia-perseris-fda/
https://www.reuters.com/article/us-indivior-dr-reddys/u-s-court-expedites-indivior-rivals-appeal-to-re-launch-generic-drug-idUSKBN1KK0N8
https://www.biospectrumasia.com/news/48/11343/luye-pharma-receives-china-approval-for-cns-drug.html
https://www.bloomberg.com/news/articles/2017-03-09/the-lawsuits-keep-coming-for-johnson-johnson
http://www.newsinferno.com/lawyers-investigate-invega-gynecomastia-lawsuits-against-janssen/
http://www.fiercepharma.com/marketing/bristol-myers-to-pay-19-5-million-abilify-off-label-marketing-settlement
https://www.thestreet.com/story/13877782/1/risperdal-settlement-reached-in-pennsylvania-gynecomastia-lawsuit-scheduled-for-trial-bernstein-liebhard-llp-reports.html
http://www.prnewswire.com/news-releases/risperdal-lawsuit-news-johnson--johnson-facing-at-least-13000-product-liability-claims-over-atypical-antipsychotic-medication-bernstein-liebhard-llp-reports-300351710.html
http://in.reuters.com/article/us-acadia-pharm-fda-idINKCN0XQ2L6
http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0725-2016&w=03022016&lang=eng
http://www.reuters.com/article/us-kentucky-settlement-idUSKBN0U629120151223
http://www.fiercepharma.com/story/jj-slapped-18m-verdict-risperdal-breast-growth-case/2015-11-10
http://www.newsinferno.com/new-study-warns-of-side-effect-risk-in-off-label-drug-prescribing/?
http://www.fiercepharmaasia.com/story/hk-listed-luye-shares-gain-us-fda-nda-submission-ly03004-track/2015-10-09
http://www.fiercepharma.com/story/allergan-and-richters-antipsychotic-gets-fda-ok-faces-stiff-competition/2015-09-17
http://www.forbes.com/sites/emilywillingham/2015/08/29/janssen-pharmaceutical-accused-of-hiding-risperdals-breast-effects-in-boys/
http://www.fiercepharma.com/story/sc-high-court-cuts-jjs-risperdal-marketing-penalty-back-again-124m/2015-07-09
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/53691r-eng.php
http://www.fiercepharma.com/story/jj-nears-75m-deal-risperdal-case-could-have-cost-12b/2015-05-19
http://www.fiercepharma.com/story/jury-boy-didnt-prove-jj-drug-caused-his-breast-growth/2015-03-23
http://www.nytimes.com/2015/03/02/us/psychiatric-drug-overuse-is-cited-by-federal-study.html?_r=0
http://www.fiercepharma.com/story/scs-top-court-backs-risperdal-verdict-against-jj-cuts-penalty-136m/2015-02-26
http://www.bloomberg.com/news/articles/2015-01-30/j-j-attacks-ex-fda-chief-in-male-breast-growth-case-over-drug
http://www.fiercepharma.com/story/jj-again-faces-label-marketing-claims-risperdal-case-boy-who-grew-breasts/2015-01-26